Evotec's CEO Explains Logic Behind Drug Discovery Pact With Novo Nordisk
Novo Nordisk's R&D pact with Evotec will open therapeutic possibilities for the Danish group in diabetes and obesity using small molecules, says Evotec's CEO.
You may also be interested in...
Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.
Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.